company background image
MDC

Medlab Clinical ASX:MDC Stock Report

Last Price

AU$0.078

Market Cap

AU$26.7m

7D

0%

1Y

-55.4%

Updated

24 May, 2022

Data

Company Financials +
MDC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MDC Stock Overview

Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia.

Medlab Clinical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medlab Clinical
Historical stock prices
Current Share PriceAU$0.078
52 Week HighAU$0.20
52 Week LowAU$0.077
Beta1.11
1 Month Change-25.71%
3 Month Change-35.00%
1 Year Change-55.43%
3 Year Change-80.25%
5 Year Change-90.13%
Change since IPO-61.00%

Recent News & Updates

Oct 06
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Shareholders of Medlab Clinical Limited ( ASX:MDC ) will have been dismayed by the negative share price return over the...

Oct 05
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

MDCAU BiotechsAU Market
7D0%0.5%-1.2%
1Y-55.4%-8.0%-0.009%

Return vs Industry: MDC underperformed the Australian Biotechs industry which returned -9% over the past year.

Return vs Market: MDC underperformed the Australian Market which returned 0.5% over the past year.

Price Volatility

Is MDC's price volatile compared to industry and market?
MDC volatility
MDC Average Weekly Movement10.6%
Biotechs Industry Average Movement9.9%
Market Average Movement9.3%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market4.2%

Stable Share Price: MDC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: MDC's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012n/aSean Hallhttps://www.medlab.co

Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia. Its lead drug candidate includes NanaBis, an oro–buccal administered equimolar tetrahydrocannabinol (THC) and cannabidiol (CBD) formulation as monotherapy, which is in phase 3 multi-centre, quadruple-blind, randomized- withdrawal active, and placebo-controlled clinical study for the management of opioid-requiring–bone–pain due to metastatic cancer. The company also develops NanoCelle, a patented sub-micron drug delivery platform that enhances drug solubility issues and enables faster absorption and metabolism of active ingredients.

Medlab Clinical Fundamentals Summary

How do Medlab Clinical's earnings and revenue compare to its market cap?
MDC fundamental statistics
Market CapAU$26.69m
Earnings (TTM)-AU$11.99m
Revenue (TTM)AU$4.47m

6.0x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDC income statement (TTM)
RevenueAU$4.47m
Cost of RevenueAU$2.78m
Gross ProfitAU$1.69m
Other ExpensesAU$13.68m
Earnings-AU$11.99m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.035
Gross Margin37.82%
Net Profit Margin-268.08%
Debt/Equity Ratio0%

How did MDC perform over the long term?

See historical performance and comparison
New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Medlab Clinical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-18.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MDC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MDC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MDC's revenue (26.1% per year) is forecast to grow faster than the Australian market (4.8% per year).

High Growth Revenue: MDC's revenue (26.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MDC's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Medlab Clinical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-27.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MDC is currently unprofitable.

Growing Profit Margin: MDC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.

Accelerating Growth: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).


Return on Equity

High ROE: MDC has a negative Return on Equity (-101.43%), as it is currently unprofitable.


Financial Health

How is Medlab Clinical's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MDC's short term assets (A$13.7M) exceed its short term liabilities (A$3.3M).

Long Term Liabilities: MDC's short term assets (A$13.7M) exceed its long term liabilities (A$965.6K).


Debt to Equity History and Analysis

Debt Level: MDC is debt free.

Reducing Debt: MDC has no debt compared to 5 years ago when its debt to equity ratio was 6.6%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MDC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 20.8% each year


Dividend

What is Medlab Clinical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MDC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.9yrs

Average board tenure


CEO

Sean Hall

no data

Tenure

AU$676,770

Compensation

Dr. Sean Michael Hall serves as the Chief Executive Officer at Medlab Clinical Limited and served as its Managing Director. He served as a Managing Director of Medlab Clinical Limited until November 2020....


CEO Compensation Analysis

Compensation vs Market: Sean's total compensation ($USD481.07K) is above average for companies of similar size in the Australian market ($USD287.06K).

Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: MDC's board of directors are considered experienced (7.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MDC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medlab Clinical Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Medlab Clinical Limited
  • Ticker: MDC
  • Exchange: ASX
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$26.690m
  • Shares outstanding: 342.18m
  • Website: https://www.medlab.co

Location

  • Medlab Clinical Limited
  • Building A
  • Unit A5 – A6, Botany Quarter
  • Botany
  • New South Wales
  • 2019
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.